To examine the effects of crizotinib on M phase progression, ALK expression was measured in breast cancer MCF7, neuroblastoma SH-SY5Y and IMR-32, and cervical adenocarcinoma HeLa S3 cells. Here, ALK is linked to breast carcinoma.